Drug Trial Radar · NCT07222670
A Study Assessing Safety, Tolerability, and Efficacy of INNA-051 in Preventing Respiratory Illness Due to Viral Infections in Healthy Adults 18 to 45 Years of Age
Last checked: Nov 20, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,100
Planned (sponsor's estimate)
Start
Dec 4, 2025
Primary completion
Mar 12, 2027
Study completion Apr 9, 2027
Sponsor
- Lead sponsor
- ENA Respiratory Pty LtdIndustry
- Sponsor type
- Industry
- First posted
- Oct 30, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Acute upper and lower respiratory infections are a major public health problem and a leading cause of morbidity and mortality worldwide. The purpose of this trial is to assess the safety of the investigational agent INNA-051, given intranasally, and its potential effectiveness in reducing the occurrence, severity, and/or the duration of illness resulting from respiratory virus infections. The trial will enroll generally healthy adults (age 18 - 45 years) who are at risk for exposure to viral respiratory infection, for example, due to living conditions or occupation. Participants will be treated with INNA-051 or placebo once weekly for 4 weeks (Part A) or 12 weeks (Part B) during the respiratory virus season.
Conditions
- Viral Respiratory Infection
- Viral Respiratory Illnesses
Interventions
INNA-051Drug
powder nasal spray.
PlaceboOther
powder nasal spray.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A - Number of Participants with Treatment-emergent Adverse Events (TEAEs)Time frame: Up to 8 weeks
- Part A - Percentage of Participants with TEAEsTime frame: Up to 8 weeks
- Part A - Number of participants with Serious Adverse Events (SAEs)Time frame: Up to 8 weeks
- Part A - Percentage of Participants with SAEsTime frame: Up to 8 weeks
- Part A - Number of Participants with Nasal Irritancy Questionnaire Symptoms (iTNSS Questionnaire)Time frame: Up to 4 weeks
- Part A - Percentage of Participants with Nasal Irritancy Questionnaire Symptoms (iTNSS Questionnaire)Time frame: Up to 4 weeks
- Part A - Change in White Blood Cell Count from BaselineTime frame: Baseline up to 4 weeks
- Part A - Change in Platelet Count from BaselineTime frame: Baseline up to 4 weeks
- Part A - Change in Hemoglobin from BaselineTime frame: Baseline up to 4 weeks
- Part A - Change in Alanine Transaminase (ALT) from BaselineTime frame: Baseline up to 4 weeks
- Part A - Change in Bilirubin (Total) from BaselineTime frame: Baseline up to 4 weeks
- Part A - Change in Bilirubin (Direct) from BaselineTime frame: Baseline up to 4 weeks
- Part A - Change in Alkaline Phosphatase (ALP) from BaselineTime frame: Baseline up to 4 weeks
- Part A - Change in Creatinine from BaselineTime frame: Baseline up to 4 weeks
- Part A - Change in High Sensitivity C-reactive Protein from BaselineTime frame: Baseline up to 4 weeks
- Part B - Number of Participants with TEAEsTime frame: Up to 16 weeks
- Part B - Percentage of Participants with TEAEsTime frame: Up to 16 weeks
- Part B - Number of Participants with SAEsTime frame: Up to 16 weeks
- Part B - Percentage of Participants with SAEsTime frame: Up to 16 weeks
- Part B - Number of Participants with Nasal Irritancy Questionnaire Symptoms (iTNSS Questionnaire)Time frame: Up to 12 weeks
- Part B - Percentage of Participants with Nasal Irritancy Questionnaire Symptoms (iTNSS Questionnaire)Time frame: Up to 12 weeks
- Part B - Change in White Blood Cell Count from BaselineTime frame: Baseline up to 12 weeks
- Part B - Change in Platelet Count from BaselineTime frame: Baseline up to 12 weeks
- Part B - Change in Hemoglobin from BaselineTime frame: Baseline up to 12 weeks
- Part B - Change in ALT from BaselineTime frame: Baseline up to 12 weeks
- Part B - Change in Bilirubin (Total) from BaselineTime frame: Baseline up to 12 weeks
- Part B - Change in Bilirubin (Direct) from BaselineTime frame: Baseline up to 12 weeks
- Part B - Change in ALP from BaselineTime frame: Baseline up to 12 weeks
- Part B - Change in Creatinine from BaselineTime frame: Baseline up to 12 weeks
- Part B - Change in High Sensitivity C-reactive Protein from BaselineTime frame: Baseline up to 12 weeks
- Part B - Number of Participants with Reverse Transcription Quantitative Polymerase Chain Reaction (RT-qPCR)-confirmed Symptomatic Viral Respiratory InfectionsTime frame: Up to 12 weeks
- Part B - Area Under the Curve (AUC) of the Total Respiratory and Systemic Symptom Scores for Participants with RT-qPCR-confirmed Symptomatic Viral Respiratory InfectionsTime frame: Up to 12 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Center for Vaccine Development and Global Health (CVD)
Baltimore, Maryland · Recruiting
Naval Medical Research Command (NMRC)
Bethesda, Maryland · Recruiting
University Health Center at the University of Maryland
College Park, Maryland · Recruiting
Accellacare of Raleigh
Raleigh, North Carolina · Recruiting
Accellacare of Piedmont HealthCare
Statesville, North Carolina · Recruiting
Accellacare - Wilmington
Wilmington, North Carolina · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.